Ory Rouvio

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Yaël C. Cohen, Mor Zada, Shuang-Yin Wang et al. · Nature Medicine · 2021 · 229 citations · Full text

Hematological Malignancy, Resistance Pathways, Single Cell Sequencing +8

Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

Drorit Merkel, Kalman Filanovsky, Anat Gafter‐Gvili et al. · American Journal of Hematology · 2012 · 67 citations · Full text

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

Eli Muchtar, Moshe E. Gatt, Ory Rouvio et al. · British Journal of Haematology · 2015 · 37 citations · Full text

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

Yaël C. Cohen, Hila Magen, Noa Lavi et al. · Annals of Hematology · 2020 · 23 citations

Hematological Malignancy, Oncology, Hematology +8